BPG is committed to discovery and dissemination of knowledge
Featured Articles
3/27/2024 1:51:18 PM | Browse: 642 | Download: 1209
Publication Name World Journal of Hepatology
Manuscript ID 91355
Country India
ISSN 1948-5182 (online)
Open Access This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Copyright © The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Gastroenterology & Hepatology
Manuscript Type Minireviews
Article Title Hepatocellular carcinoma immune microenvironment and check point inhibitors-current status
Manuscript Source Invited Manuscript
All Author List Tarana Gupta and Nikhil Sai Jarpula
Funding Agency and Grant Number
Corresponding Author Tarana Gupta, MBBS, MD, Professor, Researcher, Division of Hepatology, Department of Medicine, Pandit Bhagwat Dayal Sharma Post Graduate Institute of Medical Sciences, House No. 1065A Sector 1, Rohtak 124001, Haryana, India. taranagupta@gmail.com
Key Words Hepatocellular carcinoma; Tumour immune microenvironment; Immune checkpoint inhibitor; Atezolizumab; Bevacizumab; Pembrolizumab
Core Tip Hepatocellular carcinoma (HCC) is a prototype of inflammation associated cancer. Its varied etiology from viral to alcohol and non-alcoholic steatohepatitis, tumor extent, intrahepatic spread, vascular invasion and metastases along with underlying severity of liver dysfunction make it a complex scenario for adequate management. The recent elaboration of tumor microenvironment revealing immunogenic milieu and bringing the concept of “Cold” and “Hot” tumor opened the way for evaluation of immunotherapy in HCC. In recent years, with use of immune checkpoint inhibitors, there is a paradigm shift in management of advanced and unresectable HCC. With use of combination regime including immune checkpoint inhibitors and trans arterial chemoembolization/ablation/tyrosine kinase inhibitors, there is an ongoing effort at improving disease outcomes and minimizing the adverse events.
Publish Date 2024-03-27 13:28
Citation Gupta T, Jarpula NS. Hepatocellular carcinoma immune microenvironment and check point inhibitors-current status. World J Hepatol 2024; 16 (3): 353-365
URL https://www.wjgnet.com/1948-5182/full/v16/i3/353.htm
DOI https://dx.doi.org/10.4254/wjh.v16.i3.353
Full Article (PDF) WJH-16-353-with-cover.pdf